Activation of NLRP3 inflammasome is essential for the development of many CVD. The NLRP3 inflammasome plays a clear role in different CVDs; however, because the aetiology, pathological characteristics, onset, and offset of these diseases are different, the inhibition of NLRP3 inflammasome and related pathways could be a convergent strategy for the treatments of many CVDs. Such therapies involving NLRP3 inflammasome have a high potential for applicability in the clinical setting. In addition, inhibition of the NLRP3 inflammasome pathway for CVD treatment could be a new mechanism of many existing medicines. Although more detailed research is essential to thoroughly understand the role of NLRP3 inflammasome in the pathogenesis and to identify novel CVD therapies, NLRP3 inflammasome may be considered a crucial target of the immune-inflammatory pathway. It may broaden the therapeutic field in CVDs.